Overview

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

This is a phase 1/2, open-label study to assess the efficacy, safety and pharmacokinetics of ThisCART19A (Allogeneic Anti CD19 CAR-T) in patients with refractory or relapsed CD19 positive B cell Lymphoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Chongqing University Cancer Hospital

Collaborator:

Fundamenta Therapeutics, Ltd.

Treatments:

Cyclophosphamide
Etoposide
Fludarabine